Neumora Therapeutics (NMRA) Retained Earnings (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Retained Earnings of -$1.2 billion for Q1 2026, down 21.91% year-over-year from -$1.6 billion in Q1 2025, and down 4.51% quarter-over-quarter from -$1.2 billion in Q4 2025.
Neumora Therapeutics (NMRA) Retained Earnings (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Retained Earnings history runs 5 years deep, the most recent figure standing at -$1.2 billion for Q1 2026.
- In Q1 2026, Retained Earnings fell 21.91% year-over-year to -$1.2 billion; the TTM figure through Mar 2026 stood at -$1.2 billion (down 21.91% YoY), while the FY2025 annual figure was -$1.2 billion, down 25.01% from the prior year.
- Retained Earnings for Q1 2026 stood at -$1.2 billion, down from -$1.2 billion in the prior quarter.
- The five-year high for Retained Earnings was -$15000.0 in Q2 2025, with the low at -$1.2 billion in Q1 2026.
- The 5-year median for Retained Earnings is -$444.6 million (2022), against an average of -$533.2 million.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings tumbled 1246243.42% in 2024, then jumped 91.98% in 2025.
- Neumora Therapeutics' Retained Earnings stood at -$774000.0 in 2022, then surged by 90.18% to -$76000.0 in 2023, then sank by 1246243.42% to -$947.2 million in 2024, then slipped by 25.01% to -$1.2 billion in 2025, then dropped by 4.51% to -$1.2 billion in 2026.
- Business Quant data shows NMRA's Retained Earnings at -$1.2 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | -1.24 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.24 Bn |
| Dec 31, 2025 | -1.18 Bn |
| Sep 30, 2025 | -1.12 Bn |
| Jun 30, 2025 | -15,000.00 |
| Mar 31, 2025 | -1.02 Bn |
| Dec 31, 2024 | -947.22 Mn |
| Sep 30, 2024 | -888.40 Mn |
| Jun 30, 2024 | -187,000.00 |
| Mar 31, 2024 | -148,000.00 |
| Dec 31, 2023 | -76,000.00 |
| Sep 30, 2023 | -311,000.00 |
| Dec 31, 2022 | -774,000.00 |